Skip to main content

Pfizer Inc (PFE-N) Quote

Newsletters Subscribe Register My account My account AdChoices
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 43.83
Day High 44.46
Open:43.94
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Trailing Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Latest
A simple stock-picking strategy that has trounced the market year after year Subscriber content Norman Rothery
Norman Rothery
At midday: Materials stocks lead TSX higher
Before the Bell: Wall Street sees gains ahead of Apple results; TSX futures rise as economy grows Subscriber content
Pfizer separates its consumer health unit in business restructuring
Before the Bell: Wall Street rattled as trade row escalates; TSX futures hit by falling oil, expected rate hike Subscriber content
Health care needs a place in your portfolio. Here’s the best ETF for adding income Subscriber content Gordon Pape
Gordon Pape
Description
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings zacks

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

View Estimates zacks

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Download Report (PDF) Thomson Reuters

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Download Report (PDF) StockCalc

Latest Press Releases

More Stories
The New York Academy of Medicine to Host Special Conversation with Four Former U.S. Surgeons General on October 15
PR Newswire - Mon Sep 24, 10:21AM CDT
PR Newswire - CMTX
Mon Sep 24, 10:21AM CDT
On October 15 at 6:00pm, The New York Academy of Medicine will host an intimate conversation with four former U.S. Surgeons General: Antonia Novello, MD, MPH, DrPH, Joycelyn Elders, MD, MS, David Satcher, MD, PhD, and Richard Carmona, MD, MPH, FACS. Freda Lewis-Hall, MD, DFAPA, Executive Vice President and Chief Medical Officer, Pfizer Inc., will moderate the discussion.
Immutep Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany, and Pfizer
GlobeNewswire - Mon Sep 24, 7:00AM CDT
GlobeNewswire - CMTX
Mon Sep 24, 7:00AM CDT
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company") is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc., to evaluate the combination of Immutep's lead immunotherapy product candidate eftilagimod alpha ("efti" or "IMP321") with avelumab*, a human anti-PD-L1 antibody, in patients with advanced solid malignancies.
Global Moyamoya Market Report 2018 : Data Includes Research & Development News, Patient Uprising Explored Through 2018-2023
Heraldkeeper - Mon Sep 24, 4:55AM CDT
Heraldkeeper - CMTX
Mon Sep 24, 4:55AM CDT
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 41.09 +6.91% increase
on 08/31/18
Period Open:42.40
Price movement based on the high, low and last over the given period.
44.46 -1.18% decrease
on 09/24/18
 +1.53 (+3.61%) increase
since 08/24/18
3-Month 36.00 +22.03% increase
on 07/02/18
Period Open:36.51
Price movement based on the high, low and last over the given period.
44.46 -1.18% decrease
on 09/24/18
 +7.42 (+20.32%) increase
since 06/22/18
52-Week 33.20 +32.32% increase
on 02/09/18
Period Open:35.96
Price movement based on the high, low and last over the given period.
44.46 -1.18% decrease
on 09/24/18
 +7.97 (+22.16%) increase
since 09/22/17

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2018.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement